DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gm2wtg/europe_orphan) has announced the addition of the "Europe Orphan Drugs Pipeline Analysis" report to their offering.
This Europe Orphan Drugs Pipeline Analysis report gives a comprehensive insight into the various drug profiles under the Orphan Drugs status in Europe. This research report covers all of the ongoing drug developments through various phases. Each drug profile includes detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drugs in the development process is represented in the form of tables and detailed analysis including the available Pharmacodynamics and Pharmacokinetics results.
It has been estimated that Europe has witnessed more than 50 therapies for rare diseases being approved since 2000 onwards, when the European Commission introduced incentives to encourage the development of these drugs. The share of R&D for orphan medicinal products development as a proportion of total biopharmaceutical industry's has been increasing significantly over the years. This is strengthened by the fact that almost all companies which have been set up recently to develop orphan medicinal products have their extensive R&D plants and staff located in the European Union. This shows the significance of the region and its level of attractiveness.
This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the drug development process. This report also helps drug development organisation to keep a track record of the ongoing drug profiles being developed by their key competitor in the industry.
Following parameters for each drug profile in development phase are covered in Europe Orphan Drugs Pipeline Analysis research report:
- Drug Profile Overview
- Active Indication
- Phase of Development
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- Patent Information
- Molecular Formula
- Brand Names
- Development Agreements
- ATC Codes
Key Topics Covered:
1. Europe Orphan Drugs Market Overview
2. Development Phase: Preclinical
3. Development Phase: Phase-I
4. Development Phase: Phase-I/II
5. Development Phase: Phase-II
6. Development Phase: Phase-II/III
7. Development Phase: Phase-III
8. Development Phase: Preregistration
9. Development Phase: Registered
For more information visit http://www.researchandmarkets.com/research/gm2wtg/europe_orphan
